Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silvercorp to Acquire Adventus Creating a Diversified Mining Company (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Resverlogix Corp RVXCF


Primary Symbol: T.RVX

Healthcare Biotechnology
Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the... see more

Recent & Breaking News (TSX:RVX)

Zenith Epigenetics Announces Dosing of First Patient in Triple Negative Breast Cancer Trial with Pfizer

GlobeNewswire June 27, 2019

Resverlogix Provides Update on BETonMACE Phase 3 Epigenetics Trial

GlobeNewswire June 12, 2019

Resverlogix Announces Participation at Leading, International Scientific Conferences

GlobeNewswire June 10, 2019

Resverlogix Announces Closing of $15 Million Offering

GlobeNewswire June 7, 2019

IIROC Trade Resumption - RVX

Canada NewsWire May 15, 2019

Resverlogix Announces Pricing of Unit Offering

GlobeNewswire May 15, 2019

IIROC Trading Halt - RVX

Canada NewsWire May 15, 2019

Resverlogix Announces Proposed Offering of Units

GlobeNewswire May 14, 2019

Resverlogix Announces Publication on Apabetalone in High-Impact American Journal of Respiratory and Critical Care Medicine (AJRCCM)

GlobeNewswire May 6, 2019

Resverlogix Announces 3-Month Loan Extension

GlobeNewswire May 2, 2019

Resverlogix' BETonMACE Phase 3 Trial Successfully Reaches its Targeted 250 MACE Events

Thomson Reuters ONE April 18, 2019

Resverlogix' BETonMACE Phase 3 Trial Successfully Reaches its Targeted 250 MACE Events

GlobeNewswire April 18, 2019

Resverlogix Cognition Substudy of the BETonMACE Phase 3 Cardiovascular Trial Presented at the International Conference on Alzheimer’s & Parkinson’s Diseases

GlobeNewswire April 1, 2019

Resverlogix Announces $15.1 Million of Private Placements

GlobeNewswire April 1, 2019

Resverlogix Announces Ninth Positive Data Safety Monitoring Board Recommendation for Phase 3 Study of Apabetalone

GlobeNewswire March 27, 2019

Resverlogix Proudly Announces Funding for Phase 2 Trial Evaluating Apabetalone in Pulmonary Arterial Hypertension Led by Quebec Heart and Lung Institute – Laval University Researcher

GlobeNewswire March 18, 2019

Zenith Epigenetics Announces U.S. FDA Clearance of Investigational New Drug Application for ZEN-3694 in TNBC Program

GlobeNewswire March 18, 2019

Resverlogix Announces Participation at Prominent Industry and Investor Conferences

GlobeNewswire March 11, 2019

Resverlogix Closes $6.6 Million Private Placement with Shenzhen Hepalink

GlobeNewswire January 31, 2019

Resverlogix Announces Eighth Positive Data Safety Monitoring Board Recommendation For Phase 3 Study of Apabetalone

GlobeNewswire December 19, 2018